Eckert & Ziegler acquires remaining Shares in a Berlin Pharmaceutical Company

Berlin, 01.04.2010 - In the course of a consolidation of minority shareholding and the simplification of the corporate organisation Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) takes over the remaining 30% shares of senior shareholders of EURO-PET Berlin Zyklotron GmbH Berlin (EURO-PET) and several shareholder loans. The pharmaceutical company on the premises of the scientific campus Adlershof which specialises in the production of short-lived isotopes for nuclear imaging thus becomes a 100% affiliate of Eckert & Ziegler AG. EURO-PET remains affiliated to its senior shareholders by co-operations in sales and the licensing of new drugs which were agreed upon in the scope of the assignment of the interests.

With the complete takeover of EURO-PET Eckert & Ziegler intends to continue to boost its position on the growing market for radioactive pharmaceutical products. The Holding already has a number of radiopharmaceutical production locations in Germany and markets the approved product Yttriga®, a preliminary stage of many radiotherapy treatments, as well as fluorine-18-based radiodiagnostic compounds for nuclear medical imaging (PET). In addition, Eckert & Ziegler supplies nuclear-imaging facilities around the world with synthesis technology.

PET is the abbreviation for positron emission tomography and describes a technique which uses a special camera to make the very smallest quantities of a slightly radioactive contrast agent visible and it is used for diagnosis. This powerful and ground-breaking technology is becoming more and more important in the diagnosis of cancers and neurologic diseases like Alzheimer's because it spares the patient a burdensome marathon of diagnosis and operations carried out only on the basis of a tentative diagnosis.

The Eckert & Ziegler group with some 520 employees belongs to the largest suppliers of isotope technology components for radiation therapy and nuclear medicine world-wide. In the previous fiscal year 2009 the company made a turnover of more than EUR 100 million and earnings of some EUR 13.3 million.

The Board of Directors